| ID | 1132 |
| Name of the vaccine | Nimenrix |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | Over 6 weeks |
| Description of the vaccine | Meningococcal groups A, C, W-135 and Y conjugate vaccine. |
| Name of the manufacturer | Pfizer |
| Name of the manufacturing country | Belgium |
| Year of manufacture | 2012 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | NA |
| Vaccine formulation | Powder and a solvent for solution for injection. |
| Dosage | Primary Immunisation -
Infants from 6 weeks to less than 6 months : Two injections given 2 months apart.
Infants from 6 months of age, children, adolescents and adults : One injection.
Booster Vaccination -
Infants from 6 weeks to less than 12 months of age: One booster dose at 12 months of age, at least 2 months after the last dose. |
| Mechanism of action | Helps the body to produce its own protection (antibodies) against the bacteria. |
| Route of administration | Intramuscular |
| Indications | Protects against infections caused by Neisseria meningitidis types A, C, W-135 and Y. |
| Export | Marketing Authorisation Holder- Pfizer Europe MA EEIG |
| Approval | European Medicines Agency |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Fever, tiredness, headache, feeling drowsy, loss of appetite, swelling, pain and redness at the injection site. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.medicines.org.uk/emc/files/pil.4118.pdf |
| Other name | NA |
| Additional Links | NA
|